- Access to 2-pyridinylamide and imidazopyridine from 2-fluoropyridine and amidine hydrochloride
-
Under catalyst-free conditions, an efficient method to synthesize 2-pyridinylamides has been developed, and the protocol uses inexpensive and readily available 2-fluoropyridine and amidine derivatives as the starting materials. Simultaneously, the copper-catalysed approach to imidazopyridine derivatives has been established with high chemoselectivity and regiospecificity. The results suggest that the nitrogen-heterocycles containing iodide substituents can also be compatible for the reaction via the cascade Ullmann-type coupling, and the nucleophilic substitution reaction provides the target products in a one-pot manner.
- Chen, Lu,Huang, Shuo,Ji, Xiaoliang,Li, Jiaming,Li, Jian,Li, Yibiao,Liu, Jiasheng,Peng, Shiyong,Zhang, Kun
-
supporting information
p. 9292 - 9299
(2020/12/03)
-
- COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF
-
Disclosed are a class of coumarin-like cyclic compounds as MEK inhibitors and pharmaceutical compositions comprising the compounds, and the use of same in the preparation of a drug for treating MEK-related diseases. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof or tautomers thereof.
- -
-
Paragraph 0126-0128
(2020/05/30)
-
- HETEROCYCLIC COMPOUNDS AND USES THEREOF
-
Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
- -
-
Paragraph 0485-0487
(2019/04/25)
-
- Imidazolium chloride: An efficient catalyst for transamidation of primary amines
-
A highly efficient and convenient protocol of imidazolium chloride (30 mol %) catalyzed amidation of amines with moderate to excellent yields was reported. The protocol shows broad substrate scope for aromatic, aliphatic, and heterocyclic primary amines.
- Tian, Qingqiang,Gan, Zongjie,Wang, Xuetong,Li, Dan,Luo, Wen,Wang, Huajun,Dai, Zeshu,Yuan, Jianyong
-
supporting information
(2018/09/10)
-
- Macrocyclic derivative of pyrazole[3,4-d]pyrimidin-3-one and pharmaceutical composition and application thereof
-
The present invention relates to a macrocyclic derivative of pyrazole[3,4-d]pyrimidin-3-one as shown in the formula (I) and/or a pharmaceutically acceptable salt thereof, and a composition of a compound of the formula (I) and/or a pharmaceutically acceptable salt thereof, a preparation method thereof, application thereof as a Wee1 inhibitor and application thereof as a sensitizer for cancer chemotherapy or radiotherapy. The macrocyclic derivative of pyrazole[3,4-d]pyrimidin-3-one can effectively inhibit Wee1 and related signaling pathways, and has good cancer treatment and/or relieving effect.The formula is shown in the description.
- -
-
Paragraph 0352-0354
(2018/10/19)
-
- Synthesis and evaluation of aminopyridine derivatives as potential BACE1 inhibitors
-
To identify a new non-peptidyl BACE1 inhibitor, we focused on the aminopyridine structure, which binds to the active sites of BACE1. Synthesis of aminopyridine derivatives and evaluation of inhibitory activity against rBACE1 are described. The 2-aminopyri
- Konno, Hiroyuki,Sato, Taki,Saito, Yugo,Sakamoto, Iori,Akaji, Kenichi
-
supporting information
p. 5127 - 5132
(2015/11/09)
-
- Discovery of novel Bcr-Abl inhibitors with diacylated piperazine as the flexible linker
-
Forty-two compounds (series 8, 9 and 10) incorporated with diacylated piperazine have been synthesized and evaluated as novel Bcr-Abl inhibitors based on 'six-atom linker'. Five of them, 8d, 8h, 8l, 10m and 10p, displayed potent Bcr-Abl inhibitory activity comparable with Imatinib. Moreover, compounds 8e, 10q, 10s, and 10u were potent Bcr-Abl inhibitors with IC50 values at the sub-micromolecular level. Most compounds exhibited moderate to high antiproliferative activity against K562 cells. In particular, compound 9e was the most promising Bcr-Abl inhibitor. Docking studies revealed that the binding modes of these compounds were similar with Imatinib. These compounds could be considered as promising lead compounds for further optimization.
- Pan, Xiaoyan,Dong, Jinyun,Shi, Yaling,Shao, Ruili,Wei, Fen,Wang, Jinfeng,Zhang, Jie
-
p. 7050 - 7066
(2015/06/25)
-
- An affinity reagent for the recognition of pyrophosphorylated peptides
-
A resin-bound dinuclear zinc(II) complex for the selective capture of pyrophosphopeptides is reported. The metal complex binds diphosphate esters over other anionic groups, such as monophosphate esters, sulfate esters, and carboxylic acids, with high spec
- Conway, John H.,Fiedler, Dorothea
-
supporting information
p. 3941 - 3945
(2015/03/30)
-
- Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: Structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1)
-
The recent discovery of allosteric modulators of the CB1 receptor including PSNCBAM-1 (4) has generated significant interest in CB1 receptor allosteric modulation. Here in the first SAR study on 4, we have designed and synthesized a series of analogs focusing on modifications at two positions. Pharmacological evaluation in calcium mobilization and binding assays revealed the importance of alkyl substitution at the 2-aminopyridine moiety and electron deficient aromatic groups at the 4-chlorophenyl position for activity at the CB1 receptor, resulting in several analogs with comparable potency to 4. These compounds increased the specific binding of [3H]CP55,940, in agreement with previous reports. Importantly, 4 and two analogs dose-dependently reduced the Emaxof the agonist curve in the CB1 calcium mobilization assays, confirming their negative allosteric modulator characteristics. Given the side effects associated with CB1 receptor orthosteric antagonists, negative allosteric modulators provide an alternative approach to modulate the pharmacologically important CB1 receptor.
- German, Nadezhda,Decker, Ann M.,Gilmour, Brian P.,Gay, Elaine A.,Wiley, Jenny L.,Thomas, Brian F.,Zhang, Yanan
-
p. 7758 - 7769
(2015/01/08)
-
- Discovery of benzamide analogs as negative allosteric modulators of human neuronal nicotinic receptors: Pharmacophore modeling and structure-activity relationship studies
-
The present study describes our ongoing efforts toward the discovery of drugs that selectively target nAChR subtypes. We exploited knowledge on nAChR ligands and their binding site that were previously identified by our laboratory through virtual screenings and identified benzamide analogs as a novel chemical class of neuronal nicotinic receptor (nAChR) ligands. The lead molecule, compound 1 (4-(allyloxy)-N-(6-methylpyridin-2-yl)benzamide) inhibits nAChR activity with an IC50 value of 6.0 (3.4-10.6) μM on human α4β2 nAChRs with a ～5-fold preference against human α3β4 nAChRs. Twenty-six analogs of compound 1 were also either synthesized or purchased for structure-activity relationship (SAR) studies and provided information relating the chemical/structural properties of the molecules to their ability to inhibit nAChR activity. The discovery of subtype-selective ligands of nAChRs described here should contribute significantly to our understanding of the involvement of specific nAChR subtypes in normal and pathophysiological states.
- Yi, Bitna,Long, Sihui,González-Cestari, Tatiana F.,Henderson, Brandon J.,Pavlovicz, Ryan E.,Werbovetz, Karl,Li, Chenglong,McKay, Dennis B.
-
p. 4730 - 4743
(2013/07/26)
-
- 1H-PYROLLO[3,2-d]PYRIMIDINEDIONE DERIVATIVES
-
The present invention relates to pyrimidinedione compounds of formula (I), salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds of formula (I) or salts thereof as activa
- -
-
Page/Page column 34-35
(2012/09/22)
-
- BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR
-
The present invention provides a novel benzene derivative or thiophene derivative useful as a VAP-1 inhibitor, or a medicament for the prophylaxis or treatment of a VAP-1 associated disease and the like, namely, a compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a pharmaceutically acceptable salt thereof.
- -
-
Page/Page column 66-67
(2009/12/27)
-
- SUBSTITUTED ARYLSULFONAMIDES AS ANTIVIRAL AGENTS
-
The invention relates to substituted arylsulfonamides of formula (I) and methods for their preparation as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, particu
- -
-
Page/Page column 13
(2009/07/18)
-
- Towards allosteric receptors - Synthesis of Resorcinarene-Functionalized 2,2′-Bipyridines and their metal complexes
-
Based on a first: example of an allosteric hemicarcerand (1) we prepared four new 2,2′bipyridines that carry resorcinarene moieties in a highly convergent manner. Upon coordination to suitable transition metal ions or their complexes these compounds undergo conformational changes in a way that: they switch between "open" and. "closed" forms (2, 3, and 4) or vice versa (5), thus, bringing together or separating the two functional, moieties on the central, bipyridine, Among the transition metal complexes that act: as effectors for the conformational switching, [Re(CO)5Cl] and monomeric copper(I) complexes of sterically hindered 2,9-arylated 1,10-phenanthrolines proved, to be very effective.
- Staats, Holger,Eggers, Friederike,Hass, Oliver,Fahrenkrug, Frank,Matthey, Jens,Luening, Ulrich,Luetzen, Arne
-
experimental part
p. 4777 - 4792
(2009/12/25)
-
- MODULATORS OF CFTR
-
Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating CFTR mediated diseases using compounds of the present invention.
- -
-
Page/Page column 84
(2009/01/20)
-
- Substituted pyridines via boronic acid coupling
-
The invention relates to a convergent process for preparing a compound of the formula (V), wherein R1 is attached at the 2 or 3 position of the benzene ring, R2 is attached at the 5 or 6 position and R1, R2 and
- -
-
-
- 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof
-
To provide a composition having a steroid C17,20-lyase inhibitory activity and useful as an agent for the prophylaxis or treatment of prostatism and tumors such as breast cancer. A compound represented by the formula: wherein R is a hydrogen atom or a protecting group, R1is a lower alkyl group or a cyclic hydrocarbon group, R2is an aromatic hydrocarbon group optionally having substituents or an aromatic heterocyclic group optionally having substituents, R3is a hydrocarbon group optionally having substituents, a hydroxyl group optionally having substituents, a thiol group optionally having substituents, an amino group optionally having substituents, an acyl group or a halogen atom, and n is an integer of 0 to 4, and a salt thereof have a steroid C17,20-lyase inhibitory activity, and are useful as an agent for the pophylaxis or treatment of prostatism and tumors such as beast cancer and the like.
- -
-
-
- Derivatives of mercaptopyridine-1-oxide
-
Novel amino derivatives of mercaptopyridine-1-oxide inclusive of 2-acylamino- and 2-alkoxycarbonylamino-6-mercaptopyridine-1-oxides, disulfides thereof, and metal salts thereof having particular utility as antimicrobial agents per se and in skin cleansing detergent compositions, shampoos, hair dressings, disinfectants, preservatives and the like.
- -
-
-
